Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.33 |
| ▸ | PDE4A | P27815 | 4/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ATF4 | P18848 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | AOC2 | O75106 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2094603 | 0.83 | KAT2B (0.33) | PIK3CDELANEKAT2BBAZ2BPRMT5 | |
| SCHEMBL360662 | 0.81 | ITGB3 (0.41) | ELANEKAT2BBAZ2BPRMT5WDR77 | |
| SCHEMBL8893566 | 0.81 | PRMT5 (0.34) | PIK3CDELANEKAT2BBAZ2BPRMT5 | |
| SCHEMBL11142625 | 0.80 | EPHX1 (0.39) | ATF4CES2SMN1; SMN2 | |
| SCHEMBL8105483 | 0.80 | ELANE (0.35) | PIK3CDELANEKAT2BBAZ2BPRMT5 | |
| SCHEMBL24158596 | 0.79 | KDM4E (0.36) | PIK3CDELANEKAT2BBAZ2BPRMT5 | |
| SCHEMBL24158831 | 0.79 | KAT2B (0.42) | PIK3CDELANEKAT2BBAZ2BPRMT5 | |
| SCHEMBL21576962 | 0.79 | PIK3CD (0.38) | PIK3CDELANEKAT2BBAZ2BPRMT5 | |
| SCHEMBL11145308 | 0.78 | EPHX1 (0.42) | ATF4CES2 | |
| SCHEMBL16204627 | 0.78 | EPHX1 (0.42) | ATF4CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-3793565-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| WO-2021096860-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | PIK3CD 831/4885ELANE 1923/4885KAT2B 1279/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | PIK3CD 831/4885ELANE 1923/4885KAT2B 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.